Non-exclusive pharmaceutical rebate agreements for indacaterol and glycopyrronium bromide

Summary

The procurement concerns non-exclusive rebate agreements for medicines containing the active ingredients indacaterol and glycopyrronium bromide. Agreements are concluded under an open-house model, and purchase volumes depend on demand; no minimum quantities are guaranteed. The agreements run no later than 29 February 2028, although the procedure may be ended earlier.